sphc’s comment on DEA’s telemedicine special registration proposed rule

SPHC Regulatory Solutions supports the DEA's goal of establishing a permanent framework for telemedicine prescribing of controlled substances but has significant concerns about the proposed rule's practicality. Specifically, the rule's restrictions on prescribing certain medications, its exclusion of primary care, and the burdensome administrative requirements will likely hinder patient access and create operational challenges for providers and pharmacies. SPHC submitted comments urging the DEA to reconsider these provisions and adopt a more balanced approach that prioritizes patient care while maintaining appropriate safeguards.